ReviewInternational journal of molecular sciences2023
Application of Luteolin in Neoplasms and Nonneoplastic Diseases.
Review in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 40 citations in OpenAlex.
- Global research landscape and multisystem health mechanisms of luteolin: a comprehensive bibliometric and network pharmacology study.Frontiers in nutrition · 2026Pooled it
- An Integrated Cellular Computational Pipeline Decodes Luteolin to Design Possible Allosteric CDK1/CYCLIN B1 Inhibitors That Overcome Breast Cancer Stemness.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Network pharmacology and experimental validation to explore the effects and mechanisms of flavonoids luteolin and chrysoeriol against non‑small cell lung cancer.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- GALNT10 Affects O-Glycosylation of IGFBP7 to Promote Tumor Vascular Remodeling and Metastasis of Ovarian Cancer.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Luteolin reprograms macrophage polarization via the STING-TBK1 pathway to accelerate bone repair.Acta biochimica et biophysica Sinica · 2026Article
- Lactylation in cancer: molecular mechanisms and advances in clinical study.Molecular cancer · 2026Review
- Mechanistic analysis of luteolin in mitigating dry age-related macular degeneration through network pharmacology and experimental validation.Scientific reports · 2025Article
- Identification of potential molecular targets of luteolin in the treatment of hepatocellular carcinoma based on network pharmacology and transcriptome sequencing technology.Discover oncology · 2025Article
- Cadmium Inhibits Proliferation of Human Bronchial Epithelial BEAS-2B Cells Through Inducing Ferroptosis via Targeted Regulation of the Nrf2/SLC7A11/GPX4 Pathway.International journal of molecular sciences · 2025Article
- Baicalein-mediated regulation of Nrf2/ARE, NFĸB, and MAPK signaling in Huntington's disease: a promising strategy against neuroinflammation and neurodegeneration.Inflammopharmacology · 2025Review
- Phytochemical profiling and biological activity of the ethanolic extract ofOpen veterinary journal · 2025Review
- Korean Mistletoe (Antioxidants (Basel, Switzerland) · 2025Article
- Development of Polymeric Nanoparticles Loaded withInternational journal of molecular sciences · 2025Article
- Inhibitory effect of luteolin on the metabolism of vandetanibFrontiers in pharmacology · 2025Article
- Luteolin: exploring its therapeutic potential and molecular mechanisms in pulmonary diseases.Frontiers in pharmacology · 2025Review
- Preliminary Evidence on Safety and Clinical Efficacy of Luteolin for Patients With Prostate Cancer Under Active Surveillance.Prostate cancer · 2025Article
- Luteolin inhibits diffuse large B-cell lymphoma cell growth through the JAK2/STAT3 signaling pathway.Frontiers in pharmacology · 2025Article
- Mechanism of a Novel Complex: Zinc Oxide Nanoparticles-Luteolin to Promote Ferroptosis in Human Acute Myeloid Leukemia Cells in Vitro.International journal of nanomedicine · 2025Article
- QingGan LiDan capsules improved alcoholic liver injury by regulating liver lipid transport and oxidative stress in mice.Frontiers in pharmacology · 2025Article
- Interrelation of Natural Polyphenol and Fibrosis in Diabetic Nephropathy.Molecules (Basel, Switzerland) · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 2 countries.
Funding
Abstract
Researchers are amazed at the multitude of biological effects of 3',4',5,7-tetrahydroxyflavone, more commonly known as luteolin, as it simultaneously has antioxidant and pro-oxidant, as well as antimicrobial, anti-inflammatory, and cancer-preventive, properties. The anticancer properties of luteolin constitute a mosaic of pathways due to which this flavonoid influences cancer cells. Not only is it able to induce apoptosis and inhibit cancer cell proliferation, but it also suppresses angiogenesis and metastasis. Moreover, luteolin succeeds in cancer cell sensitization to therapeutically induced cytotoxicity. Nevertheless, apart from its promising role in chemoprevention, luteolin exhibits numerous potential utilizations in patients with conditions other than neoplasms, which include inflammatory skin diseases, diabetes mellitus, and COVID-19. This review aims to present the multidimensionality of the luteolin's impact on both neoplastic and nonneoplastic diseases. When it comes to neoplasms, we intend to describe the complexity of the molecular mechanisms that underlay luteolin's anticancer effectiveness, as well as to prove the usefulness of integrating this flavonoid in cancer therapy via the analysis of recent research on breast, colon, and lung cancer. Regarding nonneoplastic diseases, this review aims to emphasize the importance of researching the potential of luteolin in areas such as diabetology, virology, and dermatology as it summarizes the most important discoveries in those fields regarding its application.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.